CLSA ON SUN PHARMA: ET NOW
* SPARC's R&D pipeline has strengthened over the last year
* Products in areas that Sun is focusing on with aims to emerge as specialty pharma player
* SPARC expects 2 products licensed to Sun, manufactured at Halol to be launched in medium term
* 2 product launched from Halol suggest confidence in Sun's remedial work
* Recently announced out-licensing deal of novel psoriasis drug in EU is a positive
* Benign competitive environment for gGleevec in US could lift FY17 EPS by 3%
* Sun making gradual progress after tough FY16; USFDA resolution for Halol is key stock driver
IDFC ON JUST DIAL: ET NOW
* Downgrade to underperform; cut target to `430 from `650
* Stock underperformed Mid-Cap Index by ~50% YTD; trend unlikely to reverse in near term
* Underperformance largely led by slower-than-expected ramp up in JD Omni product
* Delayed Search Plus launch, structural pressure in core search biz leading to underperformance
* Addition of feet-on-street, promotional spend should trigger 250-300 bps dip in operating margins
* Believe valuation (~25x FY17E EPS) de-rating will continue over the next 6-9 months
CLSA ON RIL: ET NOW
* Maintain conviction buy, target at `1350
* Jio will need to keep Arpus high to ensure reasonable return on $22bn telecom capex
* Jio will need to attract large subscriber base to ensure reasonable return
* Believe Jio will achieve Arpu balance in its tariff strategy
* Jio will milk large capacity advantage, offer larger data and voice packets at same monthly spend
* Slashing of unit pricing, engaging content apps may be used to entice subscribers to spend more
* Launch of Jio in less than three months will be a key trigger
DB ON JSW STEEL: ET NOW
* Maintain Buy, Target `1976
* Impressive growth in crude steel production with ~19% YoY growth in July'16 to 1.34mt
* Sustained policy support limits downside to domestic steel prices from global steel price weakness
* Supported by re-commissioning of blast furnaces at all 3 key upstream locations
* Conservative estimates factor in ~18% sales growth in FY17, significant scope for upside risk
* Remain positive on both the volume and profitability outlook
NOMURA ON CUMMINS INDIA: ET NOW
* Maintain Reduce, Target `690
* Revenue growth driven by sequential improvement in exports & stable domestic performance
* Operationally in-line but lower other income leads to PAT miss
* Exports falter on unsustainably high base from previous year
* Domestic sales growth stable at +9% YoY, lower than medium term trajectory of mid teens
* Weakening Powergen sales from slowdown in real estate, will lead to muted domestic growth
MACQUARIE ON FORTIS HEALTHCARE: ET NOW
* Maintain outperform, target at `250
* Believe current levels provide attractive entry opportunity with 12-month view
* Believe demerger, separate listing of SRL will help unlock significant value for Fortis shareholders
* Standalone Hospital business is a large part of the current valuation
* Mgmt guiding for strong sequential growth in EBITDA for Hospitals biz going ahead
* Fortis trading at attractive valuations of 11.5x FY18E EV/EBITDA
CS ON ARVIND: ET NOW
* Maintain outperform, target at `380
* Brand performance remains strong; Mgmt expects growth rates to sustain for FY17
* Textile segment stable; Mgmt expects 8-9% growth in textiles for full year
* Recent rise in cotton prices could hurt textile margins in next 2 quarters unless prices correct again
* GST can be a risk in the near term after implementation
* Arvind remains strong brand story medium term; its progress is encouraging
* Maintain buy, revised target at `362 from `366
* Branded apparels biz reported a strong 26% YoY growth with a 4.3% LTL growth
* Mgmt highlighted that 'Unlimited' stores achieved cash break-even with 16% LTL for 1QFY17
* Volume-led growth in woven and garments led to beat in textiles biz revenues
* Arvind is looking to aggressively pare debt through sale of non-core assets
* Co looking for JV opportunities with global companies in technical textiles
You received this message because you are subscribed to the Google Groups "LONGTERMINVESTORSRESEARCH" group.
To unsubscribe from this group and stop receiving emails from it, send an email to longterminvestorsresearch+unsubscribe@googlegroups.com.
Visit this group at https://groups.google.com/group/longterminvestorsresearch.
For more options, visit https://groups.google.com/d/optout.
No comments:
Post a Comment